Portfoliotracker

Protara Therapeutics, Inc.

TARA · NASDAQGM · Healthcare Biotechnology 14/100 E

2,380 $
▼ −0,150 (−5,93 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 12:40
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score14 / 100 Market cap150 mil. $ P/E– Forward P/E-1,4 P/S– P/B1,1 EV/EBITDA– Dividend yield– FCF yield-37,74 % EPS-1,39 $ Net margin0,0 % Return on equity-57,4 % Beta1,54 Debt / equity0,02
52-week range 2,09 to 7,82
3-month average volume1,0 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Employees
46
Country
United States
Fiscal year end
31. 12.
Data since
22. 10. 2014

Explore further

Similar companies LRMRTRVIPMVPMNPRKRSA

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account